PPT-PATENT REFORM

University of Rochester KATHRYN DOYLE PhD JD RIVERSIDE LAW LLP COMPONENTS AND DATES FOR IMPLEMENTATION First Inventor to File Novelty Nonobviousness Inventor Oath or Declaration Fees 15 Surcharge. Assignments and Other Information that only Attorneys find Useful and Interesting. Justin R. . Nifong. Disclaimer. These materials are public information and have been prepared for entertainment purposes only to contribute to the fascinating study of intellectual property law. No rights, warranties, or other guarantees are provided herein. Everyone else’s disclaimers are hereby incorporated by reference in their entirety. . Dimitrios T. Drivas. April 8, 2015. Fordham IP . Institute: 2C. . U.S. Patent Law. U.S. . Supreme Court. 35 U.S.C. § 285, Exceptional Case Standard for Award – . Octane Fitness v. ICON . Octane Fitness LLC v. ICON Health & Fitness, . Dimitrios T. Drivas. April 24, 2014. Fordham IP Institute: 2C. U.S. Patent Law. U.S. SUPREME COURT. 2. Declaratory Judgment Burden of Proof . – . Medtronic v. . Mirowski. Medtronic, Inc. v. . Mirowski. When The Hunters Become the Hunted. John L. Capone, Esq.. About The LEGAL TECH 2013 Series. It’s a regulated world out there, especially at the intersection of IT and the law. Don’t go it alone. This series of breakfast seminars sponsored with the law firm of Duffy & Sweeney and designed to address the most compelling legal issues that impact technology. Moderated by Chuck Schmidt, a partner in the IP and technology law practice, the seminars will offer big-picture insight and best-practices as well as answers to your specific questions.. June 2013. Table of Contents. 1. Case . Law . ..................................................................................................................... § 101 . Eligibility . ......................................................................................................... the «. antitrustization. » of FRAND: a multi-. sided. . reappraisal. ?. Professor Nicolas Petit, University of Liege. LIEN, Nanterre, 18 . June 2015. Goals of the . presentation. Patent hold-up. The . LDCs. : . The . Need for Coherence between Patent Law and Public Policies. : . Innovation, Health and Trade. 2. nd. WIPO Inter-Regional Meeting on South-South Cooperation on Patents, Trademarks, Geographical Indications, Industrial Designs and Enforcement. VALUES . DECLINING. ?. GREY . GOLD . ADVISORS, LLC Wild Dunes 2015. Is the US ANTI PATENT?. Hard to Stop . Infringers. Damages Decline. Patent Litigation is Expensive. Patent Win Rates are Low. PTO Invalidates Contested Patents. Specification. The specification has two parts: “disclosure” & “claims”. 27(3) The specification of an invention must. (a) correctly and fully . describe the invention . and its operation or use as contemplated by the inventor;. Professor Damien Geradin. Tilburg University / UCL London. EDGE Legal. University of Melbourne, 10 March 2016. What are patent assertion entities?. Patent assertion entities (“PAEs”) are firms acquiring patent portfolios, which they monetize through licensing agreements with manufacturers.. Vandana. . Mamidanna. Patent is a . sovereign right . to . exclude others from:. making, using or selling the patented invention in the patented country.. offering the patented invention for sale. importing the patented invention into the patented country.. Erik . Puknys. , . Partner. ,.  . Finnegan. Karen Robinson. , Director of Litigation. , Adobe. Kim Schenk. , . Principal. , Charles River Associates. Patrick Weston, . Senior Litigation Counsel, . . Linda . Shackle. Noble Science & Engineering Library. Room 162. 480-965-7601. http://libguide.asu.edu/patents. linda.shackle@asu.edu. . If there is . prior art. that anticipates your invention. . The Hepatitis C Treatment Revolution . Expanding Access to HIV Co-Infected and Beyond. UNITAID, MSF, WHO . IAC, Melbourne 21 July, 2014. Drugs of Interest - Hepatitis C.  . Sofosbuvir. Will likely be backbone of HCV all-oral pan-genotypic regimens.